Nucleophilic 18F-fluorination of complex molecules in activated carbocyclic aromatic position

Current Radiopharmaceuticals

Volumn 3, Issue 2, 2010, Pages 109-126

  Ermert, Johannes ^a   Coenen, Heinz H ^a  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

Carbocyclic arenes; Fluorine 18; Nucleophilic substitution; Radiofluorination

Indexed keywords

1 [2 (4 FLUOROBENZAMIDO)ETHYL] 4 (7 METHOXY 1 NAPHTHYL)PIPERAZINE; 1 [2 (4 FLUOROBENZAMIDO)ETHYL] 4 (7 METHOXY 1 NAPHTHYL)PIPERAZINE F 18; 2 HYDROXY 3 [4 (4 FLUOROBENZOYL)PIPERIDINO]TETRALIN F 18; 4 FLUORO N [2 [4 (6 TRIFLUOROMETHYLPYRIDIN 2 YL)PIPERAZIN 1 YL]ETHYL]BENZAMIDE F 18; 4 FLUORO N [4 [1 (2 METHOXYPHENYL)PIPERIDIN 4 YL]BUTYL]BENZAMIDE F 18; 4 FLUORO N [4 [1 (2,3 DICHLOROPHENYL)PIPERIDIN 4 YL]BUTYL]BENZAMIDE F 18; 4 FLUORO N METHYL N [3 [3 (THIOPHENE 2 CARBONYL)PYRAZOLO[1,5 A]PYRIMIDINE 7 YL]PHENYL]BENZAMIDE F 18; 4 FLUOROBENZOIC ACID 5 (2 PHENOXYPHENYL)[1,3,4]OXADIAZOL 2 YL ESTER F 18; 4 SPIROPERIDOL F 18; ALTANSERIN F 18; AROMATIC COMPOUND; BENPERIDOL F 18; CIPROFLOXACIN F 18; DROPERIDOL F 18; FLUANISONE F 18; FLUMAZENIL F 18; FLUORINE 18; FLUORO 3 TYROSINE F 18; FLUORO 6 NITROQUIPAZINE F 18; FLUOROESTRADIOL F 18; FLUOROLEVODOPA F 18; FLUOROMETARAMINOL F 18; FLUOROTHALIDOMIDE F 18; HALOPERIDOL F 18; LOMEFLOXACIN F 18; N (N BENZYLPIPERIDIN 4 YL) 2 FLUOROBENZAMIDE F 18; N 2 [4 N (4 FLUOROBENZAMIDO)PHENYL]PROPYL 2 PROPANESULPHONAMIDE F 18; N SEC BUTYL 1 (2 FLUORO 5 NITROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; RADIOPHARMACEUTICAL AGENT; RITANSERIN F 18; SETOPERONE F 18; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; DRUG SYNTHESIS; FLUORINATION; HYDROLYSIS; ISOTOPE LABELING; MICROWAVE IRRADIATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; RADIOFLUORINATION;

EID: 77954345952     PISSN: 18744710     EISSN: None     Source Type: Journal    
DOI: 10.2174/1874471011003020109     Document Type: Article

References (93)

1. O'Hagan, D.; Harper, D.B. Fluorine-containing natural products. J.Fluor. Chem., 1999, 100, 127-33.
2. Kirk, K.L. Selective fluorination in drug design and development:an overview of biochemical rationales. Curr. Top. Med. Chem.,2006, 6, 1447-1456.
3. Schubiger, P.A.; Lehmann, L.; Friebe, M. PET Chemistry: The Driving Force in Molecular Imaging. Ernst Schering Research Foundation Workshop 62. Springer: Heidelberg, 2007.
4. Lasne, M.C.; Perrio, C.; Rouden, J.; Barré, L.; Roeda, D.;Dollé, F.;Crouzel, C. Chemistry of beta(+)-emitting compounds based onfluorine-18. Topics Curr. Chem., 2002, 222, 201-258.
5. Welch, M.J.; Redvanly, C. S. Handbook of Radiopharmaceuticals:Radiochemistry and Applications. Wiley & Sons: New York 2002.
6. Bolton, R. Radiohalogen incorporation into organic systems. J.Labelled Comp. Radiopharm., 2002, 45, 458-528.
7. Wester, H.J. Handbook of Nuclear Chemistry. Vértes, A.; Nagy, S.;Klencsár, Z.; Eds.; Kluwer Academic Publishers: Dordrecht, 2003,Vol. 4, pp. 167-209.
8. 18F]fluoride ion,Eur. J. Org. Chem., 2008, 2853-2873.
9. Miller, P.W.; Long, N.J.; Vilar, R.; Gee, A.D. Synthesis of C-11, F-18, O-15, and N-13 Radiolabels for Positron Emission Tomogra-phy. Angew. Chem. Int. Ed. Engl., 2008, 47, 8998-9033.
10. 18F]-fluoroheptadecanoic acid in high yields via aminopolyether supported, nucleophilic fluorination. J.Labelled Comp. Radiopharm., 1986, 23, 455-466.
11. 18F]fluoroalkyl)-spiperone derivatives. Appl. Radiat. Isot., 1986, 37, 1173-1180.
12. Katsifis, A.; Hamacher, K.; Schnitter, J.; Stöcklin, G. Optimization Studies Concerning the Direct Nucleophilic Fluorination of Buty-rophenone Neuroleptics. Appl. Radiat. Isot. 1993, 44, 1015-1020.
13. Stang, P.J.; Hanack, M.; Subramanian, L.R. Perfluoroalkanesulfonicester - methods of preparation and applications in organic chemistry.Synthesis, 1982, 85-126.
14. 18F]altanserin: a radioligand for the study of serotonin re-ceptors with PET: radiolabeling and in vivo biologic behavior inrats. J. Nucl. Med., 1991, 32, 2266-2272.
15. Tan, P.Z.; Baldwin, R.M.; Fu, T.; Charney, D.S.; Innis, R.B. Rapid synthesis of F-18 and H-2 dual-labeled altanserin, a metabolically resistant PET ligand for 5-HT2a receptors. J. Labelled Comp. Ra-diopharm., 1999, 42, 457-467.
16. 18F]setoperone. J. Labelled Comp.Radiopharm., 1988; 25, 403-414.
17. 18F]N-(4-phenylbutyl)-4-(4-fluorobenzoyl)piperidine for studying serotonin 5-HT2a receptors. J. Labelled Comp. Radiopharm., 1998;41, 941-949.
18. 18F]altanserin. Appl. Radiat. Isot., 2006, 64, 989-994.
19. 18F-labelled butyrophenone neuroleptics - benperidol,haloperidol, spiroperidol, and pipamperone. J. Nucl. Med., 1985,26, 181-186.
20. 18F-labeledaryl fluorides. J. Labelled Comp. Radiopharm., 1984, 21, 533-547.
21. 18F-labelled haloperidol. J. Labelled Comp. Radi-opharm., 1985, 22, 721.
22. 18F. J. Labelled Comp. Radiopharm., 1990, 28, 73.
23. 18F]haloperidol from the chloro-precursor and its applications in PET imaging of a cat's brain. Appl. Radiat. Isot.,1997, 48, 1179-1185.
24. 18F-Labeled Positron Emission Tomography (PET) Ligands for Imag-ing the Vesicular Acetylcholine Transporter. J. Med. Chem., 2009,52, 1358-1369.
25. Tewson, T.J.; Yang, D.; Wong, G.; Macy, D.; DeJesus, O.J.; Nick-les, R.J.; Perlman, S.B.; Taylor, M.; Frank, P. The synthesis of fluorine-18 lomefloxacin and its preliminary use in human studies.Nucl. Med. Biol., 1996, 23, 767-772.
26. 18F]fluorobenzamide: A potential ligand for PET imaging of receptors. Nucl. Med. Biol., 1997, 24, 671-676.
27. 18F]Fluorobenzamido)phenyl)-propyl-2-propanesulphonamide:synthesis and radiofluorination of a putative AMPA receptorligand. J. Labelled Comp. Radiopharm., 2007, 50, 1169-1175.
28. 18F]-MPPF: A Potential Radioligand for PET Studies of 5-HT1A Receptors in Humans. Synapse 1997, 25,147-154.
29. 18F]MPPF, a Fluoro Ana- log of WAY-100635. Nucl. Med. Biol., 1998, 25, 343-350.
30. Jagoda, E.M.; Lang, L.; Tokugawa, J. Development of 5-HT1A receptor radioligands to determine receptor density and changes in endogenous 5-HT. Synapse, 2006, 59, 330-341.
31. 18F]fluoro-N-{2-[4-(6-trifluor-omethylpyridin-2-yl)piperazin-1-yl]ethyl}benzamide, a potentialPET radioligand for the 5-HT1A receptor. J. Labelled Comp. Radio-pharm., 2004, 47, 531.
32. Lu, S.Y.; Hong, J.; Musachio, J.L.; Chin, F.T.; Vermeulen, E.S.;Wikström, H.V.; Pike, V.W. Alternative methods for labeling the5-HT1A receptor agonist, 1-[2-(4-fluorobenzoylamino)ethyl]-4-(7-methoxynaphthyl)piperazine (S14506), with carbon-11 or fluorine-18. J. Labelled Comp. Radiopharm., 2005, 48, 971-981.
33. 18F-labeled dopamine D3receptor ligands as potential PET imaging agents. Bioorg. Med.Chem. Lett., 2005, 15, 4819-4823.
34. 18F-labelled derivatives of indiplon as poten-tial GABAA receptor imaging tracers for PET. J. Labelled Comp.Radiopharm., 2008, 51, 123-131.
35. 18F]fluoro-benzoyl derivativeof 7-hydroxy-6-(4-phenyl-piperidin-1-yl)-octahydrobenzo[1,4] ox-azines. Nucl. Med. Biol., 2009, 36, 17-27.
36. 11C]methyl-6-oxo-4H-imidazo [1,5-a] [1,4]benzodiazepine-3-carboxylate (RO 15.1788-11C): a specific radioligand for the in vivo study of central benzo-diazepine receptors by positron emission tomography. Int. J. Appl.Radiat Isot., 1984, 35, 973-976.
37. 18F]flumazenil and its evaluation in cynomolgus monkey by posi-tron emission tomography. Nucl. Med. Biol., 2005, 32, 109-116.
38. 18F]fluorothalidomide for the in vivostudies of angiogenesis. Nucl. Med. Biol., 2006, 33, 255-62.
39. 11C]cocaine metabolites contribute to PET im-ages of the baboon brain. J. Neurochem., 1994, 62, 1154-1162.
40. Jalilian, A.R.; Tabatabai, S.A.; Shafiee, A.; Afarideh, H.; Najafi, R.; Bineshmarvasti, M. One-step, no-carrier-added, synthesis of a18 F-labelled benzodiazepine receptor ligand. J. Labelled Comp. Ra-diopharm., 2000, 43, 545-555.
41. 18F]-5-[2-(2-chlorophenoxy)phenyl]-1,3,4-oxa-diazole-2-yl-4-fluorobenzoate: A labelled ligand for benzodi-azepine receptor. J. Radioanal. Nucl. Chem., 2004, 260, 373-377.
42. 18F-labeled chelidonine derivative as a possible antitumor agent. Appl.Radiat. Isot., 2001, 54, 407-411.
43. Ma, B.; Hankenson, K.D.; Dennis, J.E.; Caplan, A.I.; Goldstein, S.A.; Kilbourn, M.R. A simple method for stem cell labeling withfluorine-18. Nucl. Med. Biol., 2005, 32, 701-705.
44. Bormans, G.; Sherman, P.; Snyder, S.E.; Kilbourn, M.R. Synthesis of carbon-11- and fluorine-18-labeled 1-methyl-4-piperidyl-4'-fluorobenzoate and their biodistribution in mice. Nucl. Med. Biol.,1996, 23, 513-517.
45. 18F]fluorobenzoate. Nucl. Med. Biol. 1999, 26, 131-138.
46. 18F]DMPPF, a new 5-HT1A ligand for PET in rats. Nucl. Med. Biol., 2006, 33, 667-675.
47. 18F]Fluoroarylketones - usefulbifunctional radiopharmaceutical intermediates. Appl. Rad. Isot.,1994, 45, 599-608.
48. 18F]RO41-0960, a potent catechol-O-methyltransferase inhibitor,for PET studies. J. Labelled Comp. Radiopharm., 1997, 39, 303-318.
49. 18F]SR46349B, a potent and selective 5-HT2 receptor antagonist.J. Labelled Comp. Radiopharm., 1995, 36, 719-728.
50. 18F]ritanserin. J. Labelled Comp. Radi-opharm., 1988, 25, 827-832.
51. Langer, O.; Mitterhauser, M.; Brunner, M.; Zeitlinger, M.; Wadsak, W.; Mayer, B.X.; Kletter, K.; Müller, M. Synthesis of fluorine-18-labeled ciprofloxacin for PET studies in human. Nucl. Med. Biol.,2003, 30, 285-291.
52. Langer, O.; Mitterhauser, M.; Wadsak, W.; Brunner, M.; Müller, U.; Kletter, K.; Müller M. A general method for the fluorine-18 la-belling of fluoroquinolone antibiotics. J. Labelled Comp. Radio-pharm., 2003, 46, 715-727.
53. Qiao, Y.; He, Y.; Zhang, S.; Li, G.; Liu, H.; Xu, J.; Wang, X.; Qi, C.; Peng, C. Syntheses and evaluation of novel F-18 labeledfluoroarylvaline derivatives: Potential PET imaging agents for tu-mor detection. Bioorg. Med. Chem. Lett., 2009, 19, 4873-4877.
54. 18F]Lu29-024: a potential PET ligandfor brain imaging of the serotonergic 5-HT2 receptor. Bioorg. Med.Chem., 2000, 8, 2511-2518.
55. 18F]fluoro-L-dopa. J.Nucl. Med., 1990, 31, 1247-1251.
56. 18F]Fluoro-L-dopa by chiral phase-transfer alkylation. Eur. J. Org.Chem., 2004, 2899-2904.
57. 18F]fluoro-L-DOPA. J. Labelled Comp.Radiopharm. 2001, 44, S146-147.
58. 18F-Fluorierung carbonylaktivierter aromatischer Ami-nosäurederivate. Berichte des Forschungszentrum Jülich, 2001;Jül-3952, 1-121.
59. Wagner, F.M.; Ermert J.; Coenen H.H. Three step, one pot radio-synthesis of 6-fluoro-3,4-dihydroxy-1-phenylalanine by isotopicexchange. J. Nucl. Med., 2009, 50, 1724-1729.
60. 200244144-A2;Chem. Abstr., 2002, 137, 20599.
61. -. J. Org. Chem.,1999, 64, 178-185.
62. 18F-Labelled Nore-phedrine Derivatives via -aminopropiophenones. J. LabelledComp. Radiopharm., 2000, 43, 1345-1363.
63. 18F-labelled sympathomimetics based on norepinephrine. J.Labelled Comp. Radiopharm., 1997, 40, 53-55.
64. Ermert J. Zur trägerarmen Markierung von Arylalkylaminen mitFluor-18 am Beispiel von Norephedrin und Metaraminol, Berichtedes Forschungszentrum Jülich, 1998, Jül-3499, pp. 1-136.
65. 18F]Fluoromethane. Appl. Radiat. Isot., 1994,45, 69-74.
66. 18F]-fluoro-4-nitronaphthyl)-cis-5-norbornene-endo-2,3-dicarboxylic imi-de. Nucl. Med. Biol., 2006, 33, 615-624.
67. Karramkam, M.; Dollé, F.; Valette, W.; Besret, L.; Bramoullé, Y.;Hinnen, F.; Vaufrey, F.; Franklin, C.; Bourg, S.; Coulon, C.; Otta-viani, M.; Delaforge, M.; Loc'h, C.; Bottlaender, M.; Crouzel, C. Synthesis of a fluorine-18-labelled derivative of 6-nitroquipazine,as a radioligand for the in vivo serotonin transporter imaging with PET. Bioorg. Med. Chem., 2002, 10, 2611-2623.
68. 18F]ADAM) as a serotonintransporter imaging agent. Appl. Radiat. Isot., 2004, 61, 1247-1254.
69. 18F]fluorophenylthio)benzylamine as a serotonin trans-porter imaging agent. Appl. Radiat. Isot., 2003, 58, 183-191.
70. 18F]ACF (2-[(2-Amino-4-chloro-5-fluorophenyl)thio]-N,N-dimethyl-benzenmethanamine). J.Med. Chem., 2002, 45, 4716-4723.
71. 18F]-ADAM, a potent serotonin transporter imagingagent. Appl. Radiat. Isot., 2009, 67, 1063-1067.
72. 18F]PK 14105 as an alternative radioligand for peripheral typebenzodiazepine binding sites. Appl. Radiat. Isot., 1990, 41, 477-482.
73. Olma, S.; Grote, M.; Sihver, W.; Ermert, J.; Coenen, H.H. Firstfluorine-18 labelling and pharmaceutical evaluation of a quinoxali-nedione derivative as putative AMPA receptor ligand. Eur. J. Nucl.Med., 2006, 33, Suppl. 2, 620.
74. Olma S. Radiofluorinated quinoxalinedione derivatives as putativeligands of the AMPA receptor, Development of synthetic strategiesand labeling. Berichte des Forschungszentrum Jülich, 2007; Jül-4252, 1-89.
75. 18F]Fluoro-5-(2-pyridinylethynyl)benzonitrile as a PET Radiotra-cer for Imaging Metabotropic Glutamate Receptor Subtype 5. Sy-napse 2007, 61, 951-961.
76. 18F-Markierung selektiverInhibitoren des Serotonin Transporters. Berichte des Forschungs-zentrum Jülich 2005, Jül-4,167, 1-112.
77. 123l-Markierung Sub-typselektiver Derivate des 5-HT1A Rezeptorliganden WAY 100635.Berichte des Forschungszentrum Jülich 2000, Jül-3895, pp. 1-133.
78. 18F]12ST05 as a potential 5-HT6 PET radioligand. Nucl. Med. Biol., 2007, 34, 995-1002.
79. 18F]bicalutamide, 4-[76Br]bromobicalutamide, and 4-[76Br]bromo-thiobicalutamide as non-steroidal androgens for prostate cancer i-maging. J. Med. Chem., 2007, 50, 1028-1040.
80. 18F-labeled dopamine D3 receptorligands as potential PET imaging agents. Bioorg. Med. Chem. Lett.,2005, 15, 4819-4823.
81. 18F-desbromo-DuP-697 as aPET tracer for cyclooxygenase-2 expression. J. Nucl. Med., 2003,44, 1700-1706.
82. 18F-labeled cyclooxygenase-2 (COX-2) inhibitor as a potential PET imaging agent. J. Labelled Comp.Radiopharm., 2006, 49, 583-593.
83. 18F-fluorination: a PET radiotracerfor studying CB1 cannabinoid receptors. J. Labelled Comp. Radio-pharm., 2003, 46, 93-98.
84. McCarthy, T.J.; Sheriff, A.U.; Graneto, M.J.; Talley, J.J.; Welch, M.J. Radiosynthesis, in vitro validation, and in vivo evaluation of18 F-labeled COX-1 and COX-2 inhibitors. J. Nucl. Med., 2002, 43,117-124.
85. 18F]NS10743. Eur. J. Nucl.Med. Mol. Imaging, 2009, 36, 791-800.
86. 11C]PIB.Bioorg. Med. Chem. Lett., 2009, 19, 602-605.
87. 18F-Labeled 2-Phenylbenzothiazoles as Positron E-mission Tomography Imaging Agents for Amyloid Plaques in Alz-heimer's Disease. J. Med. Chem., 2009, 52, 1428-1437.
88. 18F]FPBN) for in vivo detection of freeradicals. J. Labelled Comp. Radiopharm., 1995, 36, 103-110.
89. 18F]SU11248, a new potential PET tracer for imaging cancer tyro-sine kinase. Bioorg. Med. Chem. Lett., 2005; 15, 4380-4384.
90. Jonson, S.D.; Welch, M.J. Investigations into tumor accumulationand peroxisome proliferator activated receptor binding by F-18 andC-11 fatty acids. Nucl. Med. Biol., 2002, 29, 211-216.
91. Gao, M.; Wang, M.; Miller, K.D.; Sledge, G.W.; Hutchins, G.D.;Zheng, Q.H. Synthesis of radiolabeled stilbene derivatives as newpotential PET probes for aryl hydrocarbon receptor in cancers. Bi-oorg. Med. Chem. Lett., 2006, 16, 5767-5772.
92. Gao, M.; Kong, D.; Clearfield, A.; Zheng, Q.H. Synthesis of car-bon-11 and fluorine-18 labeled N-acetyl-l-aryl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolinederivatives as new potential PETAMPA receptor ligands. Bioorg. Med. Chem. Lett., 2006, 16, 2229-2233.
93. Fei, X.; Zheng, Q.H.; Wang, J.Q.; Stone, K.L.; Martinez, T.D.;Miller, K.D.; Sledge, G.W.; Hutchins, G.D. Synthesis, biodistribu-tion and micro-PET imaging of radiolabeled antimitotic agentT138067 analogues. Bioorg. Med. Chem. Lett., 2004, 14, 1247-1251.